Discovery of diphenylmethanepropionic and dihydrostilbeneacetic acids as antagonists of the integrin αvβ3

Chemical Biology and Drug Design

Volumn 67, Issue 2, 2006, Pages 177-181

  Nagarajan, Srinivasan R ^a   Meyer, Jane M ^a   Miyashiro, Julie M ^a   Engleman, V Wayne ^a   Freeman, Sandra K ^a   Griggs, David W ^a   Klover, Jon A ^a   Nickols, G Alan ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROSTILBENEACETIC ACID; DIPHENYLMETHANEPROPIONIC ACID; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; DRUG MECHANISM; DRUG SYNTHESIS; INHIBITION KINETICS; PRIORITY JOURNAL;

ACETIC ACIDS; ANIMALS; HUMANS; INTEGRIN ALPHAVBETA3; PROPIONIC ACIDS; STILBENES;

EID: 33745096791     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2006.00344.x     Document Type: Article

References (30)

1. 3. Expert Opin Ther Pat 12 : 1009 1021.
2. 3 integrin antagonists as inhibitors of bone resorption. Expert Opin Investig Drugs 9 : 1281 1291.
3. 3. Expert Opin Ther Pat 10 : 1367 1383.
4. Brooks P.C. Stromblad S. Klemke R. Visscher D. Sarkar F.H. Cheresh D.A. ( 1995) Anti-integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96 : 1815 1822.
5. 3 for angiogenesis. Science 264 : 569 571.
6. Carron C.P. Meyer D.M. Pegg J.A. Engleman V.W. Nickols M.A. Settle S.L. Westlin W.F. Ruminski P.G. Nickols G.A. ( 1998) A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res 58 : 1930 1935.
7. 3 and αvβ5 integrin receptor antagonist. Cancer Res 61 : 2232 2238.
8. Kerr J.S. Slee A.M. Mousa S.A. ( 2002) The αv integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs 11 : 1765 1774.
9. Mousa S.A. ( 1998) Mechanisms of angiogenesis in vascular disorders: potential therapeutic targets. Drugs Future 23 : 51 60.
10. Ferrara N. Alitalo K. ( 1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5 : 1359 1364.
11. Carmeliet P. Jain R.K. ( 2000) Angiogenesis in cancer and other diseases. Nature 407 : 249 257.
12. Yancopoulos G.D. Davis S. Gale N.W. Rudge J.S. Weigand S.J. Holash J. ( 2000) Vascular specific growth factors and blood vessel formation. Nature 407 : 242 248.
13. Hynes R.O. ( 2002) A reevaluation of integrins as regulators of angiogenesis. Nat Med 8 : 918 921.
14. 3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 63 : 2079 2087.
15. 3as Tumor Angiogenesis Inhibitors: the Discovery of the S257-class of Integrin Antagonist. Abstracts of Papers - 221st American Chemical Society, National Meeting, San Diego, CA, USA, April 1-5, 2001; MEDI-225.
16. 3 Integrin Receptor as Inhibitors of Angiogenesis and their Efficacy in Preclinical Animal Models of Cancer. Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, USA, March 26-30, 2000; MEDI-295.
17. 3 Integrin Receptor and their in vivo Efficacy in Animal Models of Cancer. Book of Abstracts, 218th ACS National Meeting, New Orleans, LA, USA, August 22-26, 1999; MEDI-169.
18. Pytela R. Pierschbacher M.D. Argraves S. Suzuki S. Ruoslahti E. ( 1987) Arginine-Glycine-Aspartic acid adhesion receptors. Methods Enzymol 144 : 475 489.
19. Yatohgo T. Izumi M. Kashiwagi H. Hayashi M. ( 1988) Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct 13 : 281 292.
20. Engleman V.W. Nickols G.A. Ross F.P. Horton M.A. Griggs D.W. Settle S.L. Ruminski P.G. Teitelbaum S.L. ( 1997) A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 99 : 2284 2292.
21. Mu D. Cambier S. Fjellbirkeland L. Baron J.L. Munger J.S. Kawakatsu H. Sheppard D. Broaddus V.C. Nishimura S.L. ( 2002) The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1. J Cell Biol 157 : 493 507.
22. Talley J.J. Brown D.L. Nagarajan S. Carter J.S. Weier R.M. Stealey M.A. Collins P.W. Rogers R.S. Seibert K. ( 1997) Substituted Isoxazoles for the Treatment of Inflammation. US Patent No. 5,633,272.
23. Node M. Nishide K. Fuji K. Fujita E. ( 1980) Hard acid and soft nucleophile system: 2. Demethylation of methyl ethers of alcohol and phenol with aluminum halide-phenol system. J Org Chem 45 : 4275 4277.
24. Miller W.H. Bondinell W.E. Cousins R.D. Erhard K.F. Jakas D.R. Keenan R.M. Ku T.W. Newlander K.A. Ross S.T. Haltiwanger R.C. Bradbeer J. Drake F.H. Gowen M. Hoffman S.J. Hwang S-M. et al. ( 1999) Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett 9 : 1807 1812.
25. Miller W.H. Gleason J.G. Heerding D. Samanen J.M. Uzinskas I.Y. Manley P.J. Vitronectin Receptor Antagonists. International Patent Application, WO 9945927.
26. 3) antagonists. Bioorg Med Chem Lett 13 : 1483 1486.
27. Hawes E.M. Wibberley D.G. ( 1966) 1,8-Naphthyridines. J Chem Soc (C) 3 : 315 321.
28. Moormann A.E. Yen C.H. Yu S. ( 1987) Facile synthesis of 2-aminonicotinaldehyde. Synth Commun 17 : 1695 1699.
29. Duggan M.E. Hartman G.D. Hoffman W.F. Meissner R.S. Perkins J.J. Askew B.C. Coleman P.J. Hutchinson J.H. Naylor-Olsen A.M. ( 1998) Integrin Antagonists. International Patent Application, WO 9808840.
30. 3 antagonist. J Med Chem 43 : 3736 3745.